Arcus Biosciences Says Taiho Exercised Its Option For Quemliclustat In Japan And Certain Other Territories In Asia (Excluding Mainland China)

7/8/24 6:07:11 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RCUS alert in real time by email

This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017. This is the fourth option exercise by Taiho to an Arcus program.

In exchange for the exclusive license of quemliclustat, Taiho will make an option exercise payment, as well as additional payments upon achievement of clinical, regulatory and commercialization milestones, and, if any products from the program are approved, will pay royalties on net sales of such products.

Get the next $RCUS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RCUS

Date	Price Target	Rating	Analyst
10/21/2024	$20.00	Neutral	H.C. Wainwright
10/8/2024	$29.00	Overweight	Wells Fargo
11/18/2022	$33.00	Neutral	BofA Securities
10/11/2022	$40.00	Overweight	Morgan Stanley
11/19/2021	$42.00 → $53.00	Buy	Citigroup
11/19/2021	$48.00 → $60.00	Overweight	Barclays
11/18/2021	$68.00 → $100.00	Outperform	SVB Leerink
11/9/2021	$45.00 → $48.00	Overweight	Barclays

More analyst ratings

$RCUS
Press Releases

Fastest customizable press release news feed in the world

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
Data, including overall survival, from ARC-10, a randomized study evaluating domvanalimab plus zimberelimab in front-line, PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC), will be presented in a late-breaking poster presentation An oral presentation will highlight data from an Investigator Sponsored Trial for domvanalimab and zimberelimab in anti-PD-1 refractory hepatocellular carcinoma, demonstrating further proof of concept for the Fc-silent anti-TIGIT antibody domvanalimab Arcus will discuss the ARC-10 results in more detail on its earnings call at 2:00 PM PT / 5:00 PM ET on Wednesday, November 6, 2024 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-s
10/30/24 9:00:00 AM ET
$RCUS
Biotechnology: Pharmaceutical Preparations
Health Care
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 28,600 shares of the Company's common stock at an exercise price per share of $17.33, which was the closing price on October 23, 2024, and restricted stock units to acquire a total of 14,300 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January
10/24/24 4:35:00 PM ET
$RCUS
Biotechnology: Pharmaceutical Preparations
Health Care
First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
Objective response rate of 34% (2 responses pending confirmation) and 25% (confirmed) in the 100mg daily dose expansion cohort (n=32) of ARC-20, a Phase 1/1b study of casdatifan in metastatic clear cell renal cell carcinoma (ccRCC) Low rate of primary progression (19%) and high rate of disease control (81%) was observed in the 100mg expansion cohort with many of those patients still on treatment Arcus will host a conference call to discuss these results, including results from the 50mg expansion cohort, at 5:00 AM PT / 8:00 AM ET today Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combinati
10/24/24 7:30:00 AM ET
$RCUS
Biotechnology: Pharmaceutical Preparations
Health Care

$RCUS
Leadership Updates

Live Leadership Updates

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company's Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 42,500 shares of the Company's common stock. In addition to the awards to Dr. Nuyten, the Compensation Committee granted fifteen other new emplo
8/24/22 4:05:00 PM ET
$RCUS
Biotechnology: Pharmaceutical Preparations
Health Care
Arcus Biosciences Appoints Dimitry Nuyten, M.D., Ph.D. as Chief Medical Officer
Dr. Nuyten will oversee Arcus's clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b), HIF-2a and PD-1 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Dimitry S.A. Nuyten, M.D., Ph.D has been appointed chief medical officer (CMO) effective August 1, 2022. In his role as CMO, Dr. Nuyten will oversee Arcus's clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the a
8/8/22 4:05:00 PM ET
$RCUS
Biotechnology: Pharmaceutical Preparations
Health Care
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 31,600 shares of the Company’s common stock at an exercise price per share of $30.83, which was the closing price on January 8, 2021. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08. About Arcu
1/12/21 4:10:00 PM ET
$RCUS
Biotechnology: Pharmaceutical Preparations
Health Care

First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
Objective response rate of 34% (2 responses pending confirmation) and 25% (confirmed) in the 100mg daily dose expansion cohort (n=32) of ARC-20, a Phase 1/1b study of casdatifan in metastatic clear cell renal cell carcinoma (ccRCC) Low rate of primary progression (19%) and high rate of disease control (81%) was observed in the 100mg expansion cohort with many of those patients still on treatment Arcus will host a conference call to discuss these results, including results from the 50mg expansion cohort, at 5:00 AM PT / 8:00 AM ET today Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combinati
10/24/24 7:30:00 AM ET
$RCUS
Biotechnology: Pharmaceutical Preparations
Health Care
Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Wednesday, November 6th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended September 30th, 2024. Investors interested in listening to the conference call may do so by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 940081. Participants may also register for the call online using the following link: https://www.netroadshow.com/
10/22/24 4:05:00 PM ET
$RCUS
Biotechnology: Pharmaceutical Preparations
Health Care
Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium
Data from the 100mg expansion cohort of ARC-20, a Phase 1/1b study of casdatifan in clear cell renal cell carcinoma (ccRCC), will be presented in an oral plenary session by Dr. Toni Choueiri, Dana-Farber Cancer Institute. Two posters will be presented on the preclinical evaluation and human pharmacokinetics/ pharmacodynamics of casdatifan, respectively, and a third poster will be presented on AB801, Arcus's AXL inhibitor. Arcus will also host a conference call to discuss the ARC-20 results at 5:00 AM PT / 8:00 AM ET on Thursday, October 24, 2024. Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules an
10/9/24 8:00:00 AM ET
$RCUS
Biotechnology: Pharmaceutical Preparations
Health Care

Arcus Biosciences Says Taiho Exercised Its Option For Quemliclustat In Japan And Certain Other Territories In Asia (Excluding Mainland China)

Chat with this insight

Recent Analyst Ratings for $RCUS

$RCUS Press Releases

Fastest customizable press release news feed in the world

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Arcus Biosciences Announces New Employment Inducement Grants

First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

$RCUS Leadership Updates

Live Leadership Updates

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Appoints Dimitry Nuyten, M.D., Ph.D. as Chief Medical Officer

Arcus Biosciences Announces New Employment Inducement Grants

$RCUS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Jarrett Jennifer covered exercise/tax liability with 12,670 shares, decreasing direct ownership by 6% to 190,394 units (SEC Form 4)

Chief Medical Officer Nuyten Dimitry Sa covered exercise/tax liability with 5,385 shares, decreasing direct ownership by 5% to 94,933 units (SEC Form 4)

Chief Accounting Officer Azoy Alexander sold $20,314 worth of shares (1,357 units at $14.97), decreasing direct ownership by 7% to 19,070 units (SEC Form 4)

$RCUS Market Insights

Live Market Insights